No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹815.8Prev. Close
₹814.45Turnover(Lac.)
₹612.44Day's High
₹828Day's Low
₹810.3552 Week's High
₹1,026.252 Week's Low
₹635.8Book Value
₹285.67Face Value
₹2Mkt Cap (₹ Cr.)
16,095.57P/E
22.97EPS
35.46Divi. Yield
1.4711 Jun 2025
12:00 AM
AGM
Announcement Date: 11 Jun, 2025
27 Apr 2026
12:00 AM
Board Meeting
Agenda : Audited Result
15 May 2026
12:00 AM
Dividend
Dividend Amount: 12
Record Date: 29 Jul, 2026
The pharma business also announced that it has already secured final USFDA approvals for Bosutinib Tablets in the 100 mg and 500 mg strengths.
Alembic’s version has been cleared as therapeutically equivalent to Cardizem Tablets, the reference drug marketed by Bausch Health US LLC.
The report closes the regulator’s inspection held between May 26 and May 31, 2025, confirming that the manufacturing units met compliance standards.
According to market research firm IQVIA, the US market for this formulation is estimated at around $94 million for the 12 months ending June 2025.
Alembic’s version is a generic substitute for Tegretol-XR, a medicine originally developed by Novartis.
| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 39.31 | 39.31 | 39.31 | 39.31 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5,575.95 | 5,155.43 | 4,869.6 | 4,374.98 |
Net Worth | 5,615.26 | 5,194.74 | 4,908.91 | 4,414.29 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 5,051.44 | 4,132.55 | 2,945.26 | 2,985.9 |
yoy growth (%) | 22.23 | 40.31 | -1.36 | -0.76 |
Raw materials | -1,297.91 | -1,045.89 | -892.73 | -886.29 |
As % of sales | 25.69 | 25.3 | 30.31 | 29.68 |
Employee costs | -948.27 | -806.37 | -582.72 | -527.46 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1,416.6 | 1,176.79 | 535.23 | 549.71 |
Depreciation | -152.6 | -135.67 | -101.76 | -82.9 |
Tax paid | -241.21 | -197.39 | -113.25 | -119.08 |
Working capital | -16.69 | 598.87 | 208.77 | -67.37 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.23 | 40.31 | -1.36 | -0.76 |
Op profit growth | 30.7 | 90.16 | -0.1 | -35.56 |
EBIT growth | 18.91 | 123.64 | -2.79 | -39.74 |
Net profit growth | 21.24 | 129.72 | -2 | -38.36 |
| Particulars (Rupees in Crores.) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|---|
Gross Sales | 7,344.9 | 6,672.08 | 6,228.63 | 5,652.62 | 5,305.79 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 7,344.9 | 6,672.08 | 6,228.63 | 5,652.62 | 5,305.79 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 54.66 | 56.29 | 28.31 | 2.74 | 55.74 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,976.7 | 161.14 | 4,74,396.51 | 608.7 | 0.81 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 7,425 | 73.99 | 1,96,989.63 | 756 | 0.4 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,898.3 | 84.22 | 1,86,353.62 | 467 | 0.69 | 2,677 | 222.76 |
Cipla Ltd CIPLA | 1,444.6 | 35.59 | 1,16,705.37 | 862.16 | 0.9 | 4,672.12 | 423.36 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,099.2 | 29.72 | 1,09,685.52 | 1,722 | 0.09 | 3,564.6 | 237.3 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
C R Amin
Non Independent Executive Director / CFO
Rajkumar Baheti
ED / MD / Promoter
Pranav Amin
ED / MD / Promoter
Shaunak Amin
Independent Non Exe. Director
Ashok Barat
Independent Non Exe. Director
Jai Shishir Diwanji
Independent Non Exe. Director
Manish Kejriwal
Independent Non Exe. Director
Geeta Goradia
Independent Director
Sujit J Bhayani
Company Sec. & Compli. Officer
MANISHA SARAF
Alembic Road,
Gujarat - 390003
Tel: 91-0265-2280550
Website: http://www.alembicpharmaceuticals.com/
Email: apl.investors@alembic.co.in
B-102&103 Shangrila,
Complex First Floor, Akota,
Vadodara - 390 020
Tel: 91-265-2356573/23567
Website: www.linkintime.co.in
Email: vadodara@linktime.co.in
Summary
Alembic Pharmaceuticals Limited is a leading research-driven, integrated pharmaceutical enterprise specialising in the development and manufacturing of generic formulations across diverse therapeutic ...
Read More
Reports by Alembic Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
